Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Kim ST, et al. Among authors: naing a. Nat Commun. 2022 Apr 12;13(1):1970. doi: 10.1038/s41467-022-29539-3. Nat Commun. 2022. PMID: 35413951 Free PMC article.
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Hong DS, et al. Among authors: naing a. Clin Cancer Res. 2009 Nov 15;15(22):7061-8. doi: 10.1158/1078-0432.CCR-09-1241. Epub 2009 Nov 10. Clin Cancer Res. 2009. PMID: 19903778 Free PMC article. Clinical Trial.
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Wheler JJ, et al. Among authors: naing a. Cancer Chemother Pharmacol. 2014 Mar;73(3):495-501. doi: 10.1007/s00280-014-2384-1. Epub 2014 Jan 17. Cancer Chemother Pharmacol. 2014. PMID: 24435060 Free PMC article. Clinical Trial.
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. Jardim DL, et al. Among authors: naing a. PLoS One. 2014 Feb 19;9(2):e89388. doi: 10.1371/journal.pone.0089388. eCollection 2014. PLoS One. 2014. PMID: 24586741 Free PMC article.
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Tang C, et al. Among authors: naing a. Cancer Immunol Res. 2014 Sep;2(9):831-8. doi: 10.1158/2326-6066.CIR-14-0069. Cancer Immunol Res. 2014. PMID: 25187273 Free PMC article. Review.
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR Jr, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Said R, et al. Among authors: naing a. Oncotarget. 2014 Oct 15;5(19):8937-46. doi: 10.18632/oncotarget.2339. Oncotarget. 2014. PMID: 25313136 Free PMC article. Clinical Trial.
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Falchook GS, et al. Among authors: naing a. Oncotarget. 2014 Nov 15;5(21):10280-92. doi: 10.18632/oncotarget.2163. Oncotarget. 2014. PMID: 25373733 Free PMC article. Clinical Trial.
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.
Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. Tang C, et al. Among authors: naing a. Oncoscience. 2013 Dec 11;1(1):5-13. doi: 10.18632/oncoscience.3. eCollection 2014. Oncoscience. 2013. PMID: 25593979 Free PMC article.
Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
Moon YW, Hajjar J, Hwu P, Naing A. Moon YW, et al. Among authors: naing a. J Immunother Cancer. 2015 Dec 15;3:51. doi: 10.1186/s40425-015-0094-9. eCollection 2015. J Immunother Cancer. 2015. PMID: 26674411 Free PMC article. Review.
372 results